Targeted headcount reductions and attrition Increased use of automation, including Artificial Intelligence tools Streamlined utilization of external and offshore partners Approximately $2 million from ...
LUND, Sweden, Oct. 7, 2024 /PRNewswire/ -- Hansa Biopharma AB, ("Hansa" or the "Company") (NASDAQ STOCKHOLM: HNSA), today announced positive results from a 12-month follow up analysis from the NICE-01 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results